Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medical Oncology | 25 | 2023 | 2217 | 2.650 |
Why?
|
Neoplasms | 34 | 2022 | 21507 | 1.710 |
Why?
|
Cancer Care Facilities | 6 | 2018 | 401 | 1.260 |
Why?
|
Antineoplastic Agents | 16 | 2019 | 13635 | 1.240 |
Why?
|
Quality Improvement | 16 | 2021 | 3730 | 1.200 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 3 | 2016 | 94 | 1.200 |
Why?
|
Critical Pathways | 2 | 2022 | 475 | 1.170 |
Why?
|
Medical Errors | 2 | 2023 | 1291 | 0.980 |
Why?
|
Delivery of Health Care | 8 | 2020 | 5272 | 0.920 |
Why?
|
Malpractice | 2 | 2023 | 568 | 0.770 |
Why?
|
Quality of Health Care | 8 | 2021 | 4365 | 0.760 |
Why?
|
Patient Rights | 1 | 2020 | 125 | 0.680 |
Why?
|
Lung Neoplasms | 6 | 2022 | 12985 | 0.630 |
Why?
|
Comprehensive Health Care | 1 | 2018 | 128 | 0.620 |
Why?
|
Physician-Patient Relations | 3 | 2021 | 3217 | 0.590 |
Why?
|
Palliative Care | 4 | 2021 | 3461 | 0.550 |
Why?
|
Terminal Care | 4 | 2016 | 1688 | 0.520 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 554 | 0.500 |
Why?
|
Quality Assurance, Health Care | 7 | 2015 | 2213 | 0.500 |
Why?
|
Staff Development | 1 | 2016 | 224 | 0.480 |
Why?
|
Leadership | 4 | 2021 | 1349 | 0.480 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5154 | 0.450 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1054 | 0.440 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2021 | 941 | 0.440 |
Why?
|
Hospitalization | 6 | 2018 | 10208 | 0.430 |
Why?
|
Risk Management | 3 | 2023 | 571 | 0.430 |
Why?
|
Attitude of Health Personnel | 4 | 2021 | 3844 | 0.400 |
Why?
|
Decision Support Systems, Clinical | 2 | 2017 | 1162 | 0.350 |
Why?
|
Certification | 1 | 2013 | 424 | 0.350 |
Why?
|
Decision Support Techniques | 2 | 2019 | 1957 | 0.340 |
Why?
|
Societies, Nursing | 3 | 2013 | 23 | 0.340 |
Why?
|
Motivation | 1 | 2019 | 1965 | 0.330 |
Why?
|
Education, Medical, Continuing | 1 | 2014 | 840 | 0.320 |
Why?
|
Practice Guidelines as Topic | 5 | 2014 | 7274 | 0.320 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2749 | 0.310 |
Why?
|
Faculty, Medical | 1 | 2016 | 1179 | 0.310 |
Why?
|
Information Dissemination | 1 | 2016 | 1106 | 0.300 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2410 | 0.300 |
Why?
|
Humans | 66 | 2023 | 739398 | 0.300 |
Why?
|
Telemedicine | 2 | 2021 | 2844 | 0.280 |
Why?
|
Ambulatory Care | 2 | 2014 | 2711 | 0.280 |
Why?
|
Drug Therapy | 1 | 2009 | 497 | 0.280 |
Why?
|
Program Evaluation | 5 | 2018 | 2484 | 0.270 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 3908 | 0.260 |
Why?
|
Caregivers | 1 | 2016 | 2067 | 0.260 |
Why?
|
Decision Making | 1 | 2019 | 3854 | 0.250 |
Why?
|
Health Care Costs | 3 | 2017 | 3226 | 0.250 |
Why?
|
Administration, Oral | 5 | 2018 | 3909 | 0.250 |
Why?
|
Medicare | 3 | 2016 | 6497 | 0.230 |
Why?
|
Bone Marrow Examination | 2 | 2014 | 157 | 0.230 |
Why?
|
Education, Medical | 1 | 2015 | 1712 | 0.230 |
Why?
|
Insurance, Liability | 1 | 2023 | 102 | 0.230 |
Why?
|
Hospital Mortality | 2 | 2016 | 5305 | 0.220 |
Why?
|
Health Personnel | 1 | 2016 | 3203 | 0.220 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3143 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.210 |
Why?
|
United States | 15 | 2016 | 69573 | 0.200 |
Why?
|
Stress, Psychological | 1 | 2016 | 4212 | 0.200 |
Why?
|
Acetonitriles | 1 | 2021 | 51 | 0.200 |
Why?
|
Quality of Life | 2 | 2021 | 12640 | 0.200 |
Why?
|
Efficiency, Organizational | 2 | 2016 | 694 | 0.190 |
Why?
|
Communication | 3 | 2023 | 3722 | 0.180 |
Why?
|
Massachusetts | 4 | 2016 | 8669 | 0.170 |
Why?
|
Medically Underserved Area | 1 | 2021 | 254 | 0.170 |
Why?
|
Narration | 1 | 2021 | 213 | 0.170 |
Why?
|
Specimen Handling | 2 | 2014 | 692 | 0.170 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5128 | 0.160 |
Why?
|
Documentation | 2 | 2022 | 861 | 0.160 |
Why?
|
Feedback | 1 | 2022 | 788 | 0.160 |
Why?
|
Societies, Medical | 4 | 2016 | 3739 | 0.150 |
Why?
|
Arizona | 1 | 2016 | 106 | 0.140 |
Why?
|
Patient Care Team | 3 | 2016 | 2527 | 0.140 |
Why?
|
Program Development | 2 | 2016 | 1313 | 0.140 |
Why?
|
Bone Marrow Cells | 2 | 2014 | 2515 | 0.130 |
Why?
|
Unnecessary Procedures | 1 | 2019 | 428 | 0.130 |
Why?
|
Female | 20 | 2021 | 378853 | 0.130 |
Why?
|
Focus Groups | 2 | 2018 | 1308 | 0.120 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57650 | 0.120 |
Why?
|
Medication Errors | 2 | 2012 | 797 | 0.120 |
Why?
|
Biomedical Technology | 1 | 2016 | 221 | 0.120 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1674 | 0.120 |
Why?
|
Patient Satisfaction | 2 | 2016 | 3382 | 0.120 |
Why?
|
Peer Group | 1 | 2018 | 635 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3606 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2018 | 553 | 0.110 |
Why?
|
Anemia, Refractory | 1 | 2011 | 17 | 0.110 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 163 | 0.100 |
Why?
|
Self Administration | 1 | 2013 | 386 | 0.100 |
Why?
|
Middle Aged | 13 | 2021 | 212863 | 0.100 |
Why?
|
Insurance Carriers | 1 | 2013 | 153 | 0.100 |
Why?
|
Pandemics | 2 | 2022 | 8274 | 0.100 |
Why?
|
Quality Indicators, Health Care | 2 | 2019 | 1828 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2023 | 76631 | 0.100 |
Why?
|
Oxazolidinones | 1 | 2011 | 96 | 0.100 |
Why?
|
Anemia, Sideroblastic | 1 | 2011 | 101 | 0.100 |
Why?
|
Education | 1 | 2014 | 543 | 0.100 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1435 | 0.100 |
Why?
|
Professional Practice | 1 | 2013 | 327 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3453 | 0.100 |
Why?
|
Piperazines | 1 | 2021 | 2480 | 0.090 |
Why?
|
Acetamides | 1 | 2011 | 248 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2016 | 1008 | 0.090 |
Why?
|
Aged | 12 | 2018 | 162698 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 7897 | 0.090 |
Why?
|
Research Report | 1 | 2012 | 351 | 0.090 |
Why?
|
Male | 16 | 2018 | 349022 | 0.090 |
Why?
|
Patients | 1 | 2016 | 890 | 0.090 |
Why?
|
Pyrimidines | 1 | 2021 | 2918 | 0.090 |
Why?
|
Time Factors | 6 | 2020 | 40050 | 0.080 |
Why?
|
Hospice Care | 1 | 2016 | 671 | 0.080 |
Why?
|
Canada | 1 | 2014 | 2021 | 0.080 |
Why?
|
Databases, Factual | 1 | 2023 | 7690 | 0.080 |
Why?
|
Health Status | 1 | 2021 | 4013 | 0.080 |
Why?
|
Total Quality Management | 1 | 2009 | 274 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6516 | 0.080 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2014 | 802 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2015 | 2448 | 0.080 |
Why?
|
Employee Performance Appraisal | 1 | 2008 | 87 | 0.080 |
Why?
|
Mental Health | 1 | 2021 | 2946 | 0.080 |
Why?
|
Patient Participation | 1 | 2016 | 1441 | 0.070 |
Why?
|
Adult | 8 | 2020 | 213394 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4211 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8605 | 0.070 |
Why?
|
Patient Readmission | 1 | 2020 | 3106 | 0.070 |
Why?
|
Hospital Information Systems | 1 | 2009 | 395 | 0.070 |
Why?
|
Young Adult | 5 | 2018 | 56255 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5148 | 0.070 |
Why?
|
Teaching | 1 | 2014 | 1166 | 0.070 |
Why?
|
Risk Assessment | 2 | 2019 | 23294 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 981 | 0.070 |
Why?
|
Prosthesis-Related Infections | 1 | 2011 | 538 | 0.070 |
Why?
|
Family | 1 | 2016 | 3141 | 0.070 |
Why?
|
Clinical Competence | 2 | 2018 | 4671 | 0.070 |
Why?
|
Mortality | 1 | 2017 | 2851 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2015 | 21694 | 0.070 |
Why?
|
Estramustine | 1 | 2005 | 35 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2015 | 5058 | 0.060 |
Why?
|
Outpatients | 1 | 2013 | 1469 | 0.060 |
Why?
|
Risk Factors | 4 | 2019 | 71974 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12237 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5462 | 0.060 |
Why?
|
Survival Analysis | 1 | 2017 | 10247 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2015 | 62693 | 0.050 |
Why?
|
Odds Ratio | 1 | 2015 | 9846 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2017 | 10961 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11410 | 0.050 |
Why?
|
Carboplatin | 1 | 2005 | 800 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6726 | 0.050 |
Why?
|
Taxoids | 1 | 2005 | 661 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6318 | 0.050 |
Why?
|
Logistic Models | 1 | 2015 | 13402 | 0.050 |
Why?
|
Inpatients | 1 | 2012 | 2478 | 0.050 |
Why?
|
Prognosis | 1 | 2020 | 28901 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8039 | 0.040 |
Why?
|
Appendiceal Neoplasms | 1 | 2021 | 145 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15036 | 0.040 |
Why?
|
Social Support | 1 | 2008 | 2112 | 0.040 |
Why?
|
Internship and Residency | 1 | 2018 | 5761 | 0.040 |
Why?
|
Population Surveillance | 1 | 2008 | 2629 | 0.040 |
Why?
|
Biomedical Research | 1 | 2012 | 3301 | 0.040 |
Why?
|
Mutation | 1 | 2021 | 29658 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2009 | 1673 | 0.040 |
Why?
|
Health Services | 1 | 2021 | 757 | 0.030 |
Why?
|
Infusions, Parenteral | 1 | 2016 | 415 | 0.030 |
Why?
|
Adolescent | 2 | 2016 | 85405 | 0.030 |
Why?
|
Facility Design and Construction | 1 | 2016 | 87 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2005 | 2261 | 0.030 |
Why?
|
Cohort Studies | 3 | 2013 | 40389 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7136 | 0.030 |
Why?
|
Protein Conformation | 1 | 2021 | 4012 | 0.030 |
Why?
|
Benchmarking | 1 | 2018 | 1034 | 0.030 |
Why?
|
Health Policy | 2 | 2014 | 2655 | 0.020 |
Why?
|
Environment | 1 | 2016 | 1110 | 0.020 |
Why?
|
Electronic Health Records | 2 | 2018 | 4426 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2810 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15194 | 0.020 |
Why?
|
Polypharmacy | 1 | 2011 | 290 | 0.020 |
Why?
|
Arthroplasty | 1 | 2011 | 304 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2014 | 670 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1089 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9314 | 0.020 |
Why?
|
Erythropoietin | 1 | 2011 | 724 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1503 | 0.020 |
Why?
|
Erythrocyte Transfusion | 1 | 2011 | 565 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1832 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 53037 | 0.020 |
Why?
|
Medication Adherence | 1 | 2018 | 2047 | 0.020 |
Why?
|
Reminder Systems | 1 | 2009 | 370 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2013 | 1584 | 0.020 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 694 | 0.020 |
Why?
|
Ketoconazole | 1 | 2005 | 95 | 0.020 |
Why?
|
Mitoxantrone | 1 | 2005 | 148 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2009 | 601 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2275 | 0.020 |
Why?
|
Patient Compliance | 1 | 2015 | 2679 | 0.020 |
Why?
|
Emotions | 1 | 2016 | 2642 | 0.010 |
Why?
|
Linear Models | 1 | 2013 | 5948 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2005 | 888 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2005 | 10999 | 0.010 |
Why?
|
Reoperation | 1 | 2011 | 4192 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 5959 | 0.010 |
Why?
|
Obesity, Morbid | 1 | 2011 | 1191 | 0.010 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2011 | 1457 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1655 | 0.010 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2011 | 1458 | 0.010 |
Why?
|
Genetic Testing | 1 | 2013 | 3441 | 0.010 |
Why?
|
Medical Records | 1 | 2005 | 1413 | 0.010 |
Why?
|
Informed Consent | 1 | 2005 | 988 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3051 | 0.010 |
Why?
|
Internet | 1 | 2009 | 3048 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10362 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 9812 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 12948 | 0.010 |
Why?
|
Data Collection | 1 | 2005 | 3341 | 0.010 |
Why?
|
Anticoagulants | 1 | 2009 | 4582 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10945 | 0.010 |
Why?
|
Pain | 1 | 2005 | 4923 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 11699 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2009 | 38942 | 0.000 |
Why?
|